2024 perioperative management glp-1 receptor agonists anesthesia and periprocedural of receptor-based agonists and SGLT2 inhibitors: narrative review and the STO 🔸 Should GLP-1 RAs be

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.

Microdosing allows for: Lower overall medication exposure

Discover how GLP-1 medications reduce inflammation in rheumatoid arthritis, lupus, psoriatic arthritis & osteoarthritis

The Trump administration's grand bargain with drugmakers isn't working out as planned.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

Researchers are examining whether drugs currently approved to treat obesity and type 2 diabetes could be useful for a wider range of health challenges.